(HealthDay)—The U.S. Food and Drug Administration has expanded the approval of Skyrizi (risankizumab-rzaa) to treatment of adults with active psoriatic arthritis, the manufacturer announced Friday.
Jan 26, 2022
0
1
(HealthDay)—For adults with plaque psoriasis, tapinarof cream is better than vehicle control for reducing disease severity, according to a study published in the Dec. 9 issue of the New England Journal of Medicine.
Dec 9, 2021
0
3
(HealthDay)—For moderate-to-severe plaque psoriasis, bimekizumab is more efficacious than ustekinumab and placebo, according to a study published in the Feb. 6 issue of The Lancet.
Feb 5, 2021
0
2
Four in 10 plaque psoriasis patients achieve complete disease clearance with tapinarof cream, 1 percent, according to a study published online June 26 in the Journal of the American Academy of Dermatology.
Jul 13, 2022
0
0
(HealthDay)—Biologics seem to be associated with greater reduction in psoriasis severity scores and higher drug survival rates than methotrexate in pediatric patients treated in a real-world setting, according to a study ...
Feb 10, 2020
0
23
About half of Medicare patients who start taking biologic therapies for moderate to severe plaque psoriasis stop within a year, according to a new study led by researchers from the Perelman School of Medicine at the University ...
Apr 25, 2016
0
3
The monoclonal antibody secukinumab is approved for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of six years who are candidates for systemic therapy. The German Institute ...
Dec 4, 2020
0
3
Psoriasis is an incurable chronic disease with a hereditary component, in which the body's immune system attacks parts of the skin. This leads to scaly red patches, which can be very itchy. About two million people in Germany ...
Jun 2, 2017
0
0
